Gene delivery by lentivirus vectors
Authors:
- 17 April 2007
- journal article
- review article
- Published by Springer Nature in Molecular Biotechnology
- Vol. 36 (3) , 184-204
Abstract
The capacity to efficiently transduce nondividing cells, shuttle large genetic payloads, and maintain stable long-term transgene expression are attributes that have brought lentiviral vectors to the forefront of gene delivery vehicles for research and therapeutic applications in a clinical setting. Our discussion initiates with advances in lentiviral vector development and how these sophisticated lentiviral vectors reflect improvements in safety, regarding the prevention of replication competent lentiviruses (RCLs), vector mobilization, and insertional mutagenesis. Additionally, we describe conventional molecular regulatory systems to manage gene expression levels in a spatial and temporal fashion in the context of a lentiviral vector. State of the art technology for lentiviral vector production by transient transfection and packaging cell lines are explicitly presented with current practices used for concentration, purification, titering, and determining the safety of a vector stock. We summarize lentiviral vector applications that have received a great deal of attention in recent years including the generation of transgenic animals and the stable delivery of RNA interference molecules. Concluding remarks address some of the successes in preclinical animals, and the recent transition of lentiviral vectors to human clinical trials as therapy for a variety of infectious and genetic diseases.Keywords
This publication has 203 references indexed in Scilit:
- Silencing of HIV-1 with RNA Interference: a Multiple shRNA ApproachMolecular Therapy, 2006
- Probing tumor phenotypes using stable and regulated synthetic microRNA precursorsNature Genetics, 2005
- Second-generation shRNA libraries covering the mouse and human genomesNature Genetics, 2005
- Efficient Tet-Dependent Expression of Human Factor IX in Vivo by a New Self-Regulating Lentiviral VectorMolecular Therapy, 2005
- A resource for large-scale RNA-interference-based screens in mammalsNature, 2004
- Second‐generation tetracycline‐regulatable promoter: repositioned tet operator elements optimize transactivator synergy while shorter minimal promoter offers tight basal leakinessThe Journal of Gene Medicine, 2004
- Effective expression of small interfering RNA in human cellsNature Biotechnology, 2002
- Robust and Efficient Regulation of Transgene Expression in Vivo by Improved Tetracycline-Dependent Lentiviral VectorsMolecular Therapy, 2002
- Lentiviral Vectors: Regulated Gene ExpressionMolecular Therapy, 2000
- Quantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature, 1997